Is 5-23-05-00063 (Beilstein Handbook Reference) Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 5-23-05-00063 (Beilstein Handbook Reference)? Is 5-23-05-00063 (Beilstein Handbook Reference) safe for nursing mother and child? Does 5-23-05-00063 (Beilstein Handbook Reference) extracts into breast milk? Does 5-23-05-00063 (Beilstein Handbook Reference) has any long term or short term side effects on infants? Can 5-23-05-00063 (Beilstein Handbook Reference) influence milk supply or can 5-23-05-00063 (Beilstein Handbook Reference) decrease milk supply in lactating mothers?

Excreted into breast milk in a non-significant clinical amount. Not problems on breastfed infants of treated mothers were found. Plasma levels were low or undetectable in those infants. For a mother's dose of 400 mg three times-a-day, the intake of a breastfed infant would be less than 10% of the usual daily pediatric dose, whenever the breast-feed is done within 2-3 hours of mother's intake. Widely used for treatment of Giardia lamblia infections, even in small infants, without adverse effects reported. 5-23-05-00063 (Beilstein Handbook Reference) may produce a red discoloration of corporal fluids and bitter flavor of the milk with no harm effect on the child.

With maternal intravenous and oral therapy, breastfed infants receive 5-23-05-00063 (Beilstein Handbook Reference) in doses that are less than those used to treat infections in infants, although the active metabolite adds to the total infant exposure. Plasma levels of the drug and metabolite are measurable, but less than maternal plasma levels. Case reports of candidal infections and diarrhea have been reported, and a comparative trial suggested that oral and rectal colonization with might be more common in infants exposed to 5-23-05-00063 (Beilstein Handbook Reference). Neither topical nor vaginal 5-23-05-00063 (Beilstein Handbook Reference) have been studied during breastfeeding. After vaginal administration, plasma levels are less than 2% of those after a 500 mg oral dose. After topical administration, blood levels are about 1% of the peak plasma levels after a 250 mg oral dose. Only water-miscible cream or gel products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.[1] Because of the well demonstrated genotoxicity and mutagenicity in bacteria, carcinogenicity in animals, and possible mutagenicity in humans,[2][3] concern has been raised about exposure of healthy infants to 5-23-05-00063 (Beilstein Handbook Reference) via breastmilk.[4] The relevance of these findings has been questioned and no definitive study has yet been performed in humans.[3][5] Opinions vary among experts on the advisability of using 5-23-05-00063 (Beilstein Handbook Reference) during longer-term therapy while breastfeeding, but some sources recommend discontinuing breastfeeding for 12 to 24 hours after single-dose maternal treatment.[4][6] Other drugs are available for some conditions that 5-23-05-00063 (Beilstein Handbook Reference) is used to treat. Topical or vaginal use of 5-23-05-00063 (Beilstein Handbook Reference) during breastfeeding is unlikely to be of concern, although the manufacturer of one vaginal product recommends not breastfeeding during treatment and for 2 days after the last dose.

None of ten 5-day-old infants who were breastfed every 4 hours after a single maternal 200 mg oral dose of 5-23-05-00063 (Beilstein Handbook Reference) had any signs of oral or gastrointestinal upset during the 12-hour study period.[7] Sixteen newborn breastfed infants (aged 0 to 22 days) of mothers receiving 200 mg or 400 mg of oral 5-23-05-00063 (Beilstein Handbook Reference) 3 times daily reportedly suffered no observable adverse reactions during the 9 days of the study.[10] A case of diarrhea and secondary lactose intolerance was possibly caused by 5-23-05-00063 (Beilstein Handbook Reference) in breastmilk transmitted to the infant in the early neonatal period.[14] In a controlled, comparative study, 35 newborn infants were monitored for 10 days during maternal therapy with 5-23-05-00063 (Beilstein Handbook Reference) and another antibiotic (33 ampicillin, 1 erythromycin and 1 cephalexin) for postpartum infection or prophylaxis. Dosages and routes of administration were not stated, but some mothers received the drugs intravenously initially and then were switched to oral therapy. Compared to infants of mothers who received ampicillin alone or no antibiotics, more infants exposed to 5-23-05-00063 (Beilstein Handbook Reference) and ampicillin had very loose stools than in the other groups, especially when the drugs were given intravenously. More frequent and heavier growth of species was found in the oral and perianal swabs of 5-23-05-00063 (Beilstein Handbook Reference)-exposed infants, but this did not quite reach statistical significance (p=0.053). One infant exposed to 5-23-05-00063 (Beilstein Handbook Reference) and ampicillin developed oral thrush. No differences were found between the groups in diaper rash, feeding problems or weight gain to the time of discharge.[11]